New results from secondary analyses of the landmark PROactive Study found that ACTOS (pioglitazone HCl) significantly reduced the occurrence of fatal and non-fatal heart attacks and acute coronary syndrome (ACS) in high-risk patients with type 2 diabetes who had a previous heart attack. Importantly, these results were above and beyond those seen with standard of care treatment.
The findings, which were revealed today at the American Heart Association's Scientific Sessions 2005, build on previously-reported results from the PROactive Study, showing that ACTOS, an oral antidiabetic medication, significantly reduced the combined risk of heart attacks, strokes and death by 16 percent in high-risk patients with type 2 diabetes.
"Takeda is breaking new ground with the PROactive Study. Never before have this many high-risk people with type 2 diabetes and cardiovascular disease been studied," said Robert Spanheimer, M.D., medical director for diabetes and metabolism at Takeda Pharmaceuticals North America. "Through this innovative research, we now know that ACTOS can markedly reduce the recurrence of heart attacks."
These data assessed the effects of ACTOS on cardiovascular morbidity and mortality in 2,445 high-risk patients who had previously had a heart attack, a population that tends to have a very poor prognosis. The results show that in patients taking ACTOS on top of standard of care treatment:
- The recurrence of fatal or non-fatal heart attacks was reduced by 28 percent (P =0.045)
- The risk of acute coronary syndrome or ACS (a term used to describe potentially life-threatening, acute cardiovascular events) was reduced by 37 percent (P =0.035)
- There was a 19 percent (P=0.034) risk reduction in the cardiac composite endpoint of non-fatal heart attacks, coronary revascularization, ACS and cardiac death
"These results are very meaningful for the diabetes community, especially wPage: 1 2 3 Related medicine news :1
Contact: Jocelyn Gerst
. New study shows promise in reducing surgical risks associated with surgical bleeding2
. Most seniors now have drug coverage, U-M study shows3
. Wireless technology shows promise in diagnosing pediatric intestinal disease4
. Study shows radiofrequency ablation highly effective in treating kidney tumors5
. Method shows promise for early detection of pancreatic cancer6
. Organic farming can feed the world, U-M study shows7
. New study shows Rescue Remedy is an effective all-natural stress, anxiety reliever8
. Borderline personality disorder shows improvements with intensive psychotherapy9
. New drug shows promise in treatment of advanced thyroid cancer10
. Study shows Diachrome improves blood sugar control in people with type 2 diabetes11
. Trial shows circulating tumor cells predict how prostate cancer patients do with chemotherapy